"David, how is the development progress of ranibizumab?" In the headquarters of Novavax, an executive asked other executives about the development progress of new drugs. Ranibizumab is a new drug they developed for macular degeneration.

It is also a key project of Novavax in recent years. According to their judgment of the market, once approved by the FDA, this will be another blockbuster drug.

"Steve, the clinical trial is going very well. It won't be long before we get approval from the FDA." David said confidently, "I have already started a public relations campaign with the FDA."

Everyone knows what the public relations actions he is talking about will be: providing various comforts for professionals responsible for FDA review, helping to promote their academic works, organizing special academic conferences for them, etc. These large pharmaceutical companies

With rich operational experience, you can completely convince those reviewers.

This is one of the reasons why small pharmaceutical companies cannot afford FDA review costs. The launch of new drugs not only requires a lot of money in clinical trials, but also a large number of public relations expenses; and most importantly, those reviewers are very strict with large pharmaceutical companies.

I understand that I can safely accept their kindness, but I have never dealt with small pharmaceutical companies. Sometimes they may not dare to accept even though they want to show their kindness.

In addition, large pharmaceutical companies can use various public relations activities to quickly get their new drugs approved. So, thinking about the problem from another angle, they can also use public relations activities to prevent certain new drugs that may have an impact on them from passing approval. In order to protect themselves

They can definitely achieve the benefits.

"It's great. I believe shareholders will be very happy to hear this news!" Steve said excitedly. As senior executives, they can also get high bonuses from it.

"I'm sorry, gentlemen, I'm afraid I have to interrupt your celebration. Here's some bad news!" Steve and David were both happy, but the other executive looked grim.

"Norman, what's wrong? Is there something wrong with the development? Or is there another company's development plan that collided with ours? But I haven't received any similar news." David asked doubtfully.

"I just received an email, which told me a very unfortunate news. There is now a cheap macular degeneration treatment drug on the market. The price of this drug is only the price we plan to give Lan

The price of ranibizumab is a fraction of the price of ranibizumab, which means that ranibizumab will face the impact of cheap drugs before it has been approved." Norman said with a serious face, "This is simply too bad."

The word "cheap" is the most unheard of for pharmaceutical companies. What we do is a sacred and great cause to save human lives and maintain human health. Can human life and health be measured in money? Those who sell cheap drugs are simply too much.

Disrespecting human life and health!

"What drug is it? Why didn't I receive the news?" David and Steve looked at each other. If a company developed a similar product, how could they not know about it?

"It is not a drug specifically for macular degeneration, but an off-label drug. Some doctors have found that Roche's Avastin has a significant effect on macular degeneration, so they often prescribe this drug to patients with macular degeneration as an off-label drug. And this

This method has a tendency to spread, and we have not noticed this before." Norman showed them the printed email content, "Look, the upward curve is very obvious, which will definitely have a huge impact on our ranibizumab.

.”

"Damn it! These doctors are so irresponsible. The safety of patients is not guaranteed when using drugs off-label." David was filled with indignation. How can you use methods that are not indicated on the label? Don't these doctors know that this will affect us?

Is it a waste of money? Is the money we spend on doctors wasted? They are too unethical!

"It seems we must hold an emergency meeting immediately to find a way to solve this problem!" The executives made a prompt decision and immediately summoned other personnel to hold an emergency meeting.

Norman showed them the email he had received on the big screen, "What we need to do now is to prohibit these doctors from continuing to use off-label drugs to prescribe this drug to patients with macular degeneration. In addition, we also need to convince Roche not to use the treatment as an off-label drug."

Macular degeneration has been added to Avastin's label, please tell me what can be done?"

"We can ask the academic community to publish a special paper to analyze the comparative efficacy of Avastin and ranibizumab, and let them tell those patients that there are safety risks in using Avastin to treat macular degeneration." Someone immediately suggested.

, they don’t care as to whether there is really such a difference between the two drugs.

Novavax spends a lot of money every year to sponsor academics. They have no doubt that they will find scholars who are willing to do these studies and can produce research results that satisfy them.

"I believe Roche is not willing to sell macular degeneration treatment drugs at such a cheap price." They are both pharmaceutical giants, and they know each other's thoughts very clearly. "We can give up part of the market and let Roche help us sell ranibizumab."

, in exchange for them banning Avastin for the treatment of macular degeneration."

"In this case, we will have to raise the price, otherwise the profits earned from ranibizumab will not satisfy shareholders," Steve said.

"Roche will support price increases. Isn't that what they do with vitamin C?" Norman shrugged. They are also familiar with such things as price alliances.

"We also need to carry out public relations with the FDA and ask them to prohibit doctors from prescribing drugs for macular degeneration patients for off-label use. Of course, this must be done after the relevant papers are published." David suggested that the FDA should also take into account the impact and be honest.

An unreasonable ban is a bit excessive, but it would be different if there were several papers pointing out the safety risks of Avastin.

"Okay, let's do it. Let's start assigning tasks now. David, you are responsible for the public relations for the FDA. Steve, you go find relevant scholars; let them come up with papers as soon as possible and publish them in the "New England Journal of Medicine"

Journals of this level and above; I'll go talk to the people at Roche and listen to their conditions first!" After some discussion, Norman finished assigning tasks, packed up his things, and prepared to leave the meeting.

"Wait, there is one more thing. The Chinese branch wants us to help them put pressure on the local government to prevent a certain local drug from being launched on the market." someone said quickly.

"Ranibizumab is the most important thing now, let them handle it themselves!"
Chapter completed!